CCL17 and osteoarthritis: More recent studies have indicated that the GM-CSF → CCL17 pathway can be linked with TNF activity (103) as well as regulating experimental osteoarthritic pain and optimal disease (98)—the latter model data have led to a clinical trial being initiated in osteoarthritis using a CCL17 antagonist (NCT03485365 ClinicalTrials.gov).